版本:
中国

BRIEF-Halozyme's PEGPH20 increases immune response, effectiveness of immunotherapies in preclinical cancer models

April 3 Halozyme Therapeutics Inc:

* Halozyme's PEGPH20 increases immune response and effectiveness of immunotherapies in preclinical cancer models

* Halozyme -co and other researchers conducting further investigations to determine potential of combining pegph20 with adoptive t cell and other immunotherapies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐